Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AG Monoclonal antibodies
L04AG05 Vedolizumab
D08083 Vedolizumab (USAN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
Selective Adhesion-Molecule Inhibitor
Vedolizumab
D08083 Vedolizumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
23 Digestive organ agents
239 Miscellaneous
2399 Others
D08083 Vedolizumab (USAN); Vedolizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: other families
Integrins
ITGA4/ITGB7
D08083 Vedolizumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D08083
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D08083
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D08083
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D08083
